

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

MTA Etanercept, abatacept, adalimumab and tocilizumab for treating juvenile idiopathic arthritis (including review of TA35)

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

The following potential equality issues were identified during the scoping process:

1. There are anecdotal reports of JIA patients having their treatment discontinued at age 18 because the existing NICE guidance for etanercept (TA35) only makes recommendations for adolescents up to age 17. It will be important that the guidance does not discriminate solely according to the age of JIA patients.
2. Adults have not been considered in previous NICE guidance. Unless this review covers adults with JIA (or there is a plan on how this will be assessed), this group will be discriminated against.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

1. NICE can only make recommendations for treatments in line with the marketing authorisations of these treatments. TA35 could only make recommendations for etanercept treatment in people aged 4 to 17 years because this age was specified in the marketing authorisation at that time.
2. The current appraisal will seek clarification from the EMA and the

Technology Appraisals: Scoping

Equality impact assessment for the proposed Multiple Technology Appraisal of etanercept, abatacept, adalimumab and tocilizumab for treating juvenile idiopathic arthritis (including review of TA35)

Issue date: October 2014

companies as to the interpretation of the wording in the marking authorisations for the technologies appraised. The Committee will consider age groups accordingly and also in line with on the evidence presented.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No. The scope refers to '*people with...*' in order to allow an exploration of the age range for which these technologies are licensed, and for which evidence is available.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholder related to potential equality issues were identified during the scoping process.

Approved by Associate Director (name): Elisabeth George

Date: 17/10/2014